drug_type
RELEVANT_DRUG
intervention_type
cellular therapy
drug_description
Gene-modified autologous T cells expanded with IL-7/IL-15 and engineered to express a CD19-specific scFv with 4-1BB/CD3ΞΆ signaling; redirects T cells to kill CD19+ malignant B cells, with 4-1BB enhancing expansion and persistence.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD19-specific CAR (scFv linked to 4-1BB and CD3zeta). Binding to CD19 on malignant B cells triggers T-cell activation and cytotoxic killing; 4-1BB costimulation enhances expansion and persistence. Cells are expanded ex vivo with IL-7/IL-15.
drug_name
Autologous anti-CD19 CAR T cells
nct_id_drug_ref
NCT06762431